
## **FREEWAY<sup>™</sup>**

**LONG-TERM STUDY** 

Proven 5-year Safety and Efficacy


5-year follow up of the randomized, multicenter Freeway Stent Study<sup>1</sup>




### **FREEWAY**<sup>™</sup>

Drug Eluting Balloon for peripheral interventions









Significantly reduced need for clinically-driven target lesion revascularization at 5 years (p=0.032)



No elevated mortality



No trend for any accumulation of causes of death in both groups



No difference in administered paclitaxel dose in alive vs. died patients



No difference in minor or major amputations in both groups

#### Freeway Stent Study<sup>1</sup>


Freeway Long-term Study<sup>2</sup>

12 months follow-up (n=98)

5-year follow-up (n=75)

12 months follow-up (n=79)

5-year follow-up (n=73)



5-year data shows significantly better efficacy while ensuring long-term safety



<sup>&</sup>lt;sup>1</sup> Tacke et al. "The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment." CVIR 2019 42(11): 1513-1521

 $<sup>^2</sup>$  Hausegger et al. "Long-term follow-up and mortality rate of patients of the randomized Freeway Stent Study." CVIR 2024 47(2): 186-193.

### **FREEWAY™**

# DEB – Drug Eluting Balloon for peripheral interventions – One step ahead



Proven 5-year safety and efficacy



**Amorphous coating technology** 



**Enables re-intervention** 



Wide spectrum of balloon catheters



#### **Eurocor Tech GmbH**

In den Dauen 6a, 53117 Bonn Germany

Phone: +49 (0)228 / 20 15 0-0 Fax: +49 (0)228 / 20 15 0-5 info@eurocor.de, eurocor.de Eurocor Tech GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Ltd and is part of the Opto Circuits Group.

The device fulfils the requirements for CE marking – Notified Body 1434.

Rev. Nr.: 0825 F FW FLS EN

